ARVN Q2 2021 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-4.3% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$52M-943.6% margin

Net Income

-$50M-914.5% margin

EPS (Diluted)

$-1.03

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$48M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$644M

Total Liabilities

$61M

Stockholders' Equity

$583M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$6M	-4.3%
Gross Profit	$6M	$6M	-4.3%
Operating Income	-$52M	-$26M	-96.0%
Net Income	-$50M	-$25M	-99.4%